Search results
Results from the WOW.Com Content Network
Today, Moderna's trailing-12-month revenue is just over $5 billion, and it reported operating losses of $2.7 billion. That means the pressure is on for it to produce in-demand medicines precisely ...
In data released Wednesday, Moderna showed better protection against breakthrough cases after 8 months from the first dose compared to after a year. But the most benefit will be derived from the ...
In a study of more than 50,000 patients in the Mayo Clinic Health System https://bit.ly/37Btmhf, researchers found the effectiveness of Moderna's vaccine against infection had dropped to 76% in ...
Since then, though, Moderna has traveled along a rough path. On top of this, at the JPMorgan Healthcare conference this week, Moderna lowered its 2025 revenue guidance, and announced more than $1 ...
Moderna’s total revenue for Q3 2023 was $1.8 billion, compared to $3.4 billion in the same period in 2022, the company reported on Thursday. This is mainly due to a decrease in sales of the ...
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...
mRNA-4157/V940 was initially developed by Moderna starting in 2017. In May 2018, Moderna and MSD (Merck in US) announced collaboration on further development of the investigational agent. In 2019 Moderna and Merck jointly put mRNA-4157/V940 into clinical trials in combination with Merck's cancer immunotherapy drug pembrolizumab in resected ...